Shanghai Junshi Biosciences Co., Ltd.

SEHK:1877 Stock Report

Market Cap: HK$26.7b

Shanghai Junshi Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

Shanghai Junshi Biosciences has a total shareholder equity of CN¥6.3B and total debt of CN¥2.8B, which brings its debt-to-equity ratio to 43.8%. Its total assets and total liabilities are CN¥10.9B and CN¥4.6B respectively.

Key information

43.8%

Debt to equity ratio

CN¥2.75b

Debt

Interest coverage ration/a
CashCN¥3.04b
EquityCN¥6.28b
Total liabilitiesCN¥4.58b
Total assetsCN¥10.86b

Recent financial health updates

Recent updates

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Oct 14
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Sep 30
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Aug 29
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Jun 28
Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

May 06
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Mar 22
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Jan 26
Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Dec 17
Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Nov 20
Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Sep 05
Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

May 22
Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

May 01
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Jan 16
A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 03
Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Oct 12
Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Financial Position Analysis

Short Term Liabilities: 1877's short term assets (CN¥4.6B) exceed its short term liabilities (CN¥2.3B).

Long Term Liabilities: 1877's short term assets (CN¥4.6B) exceed its long term liabilities (CN¥2.3B).


Debt to Equity History and Analysis

Debt Level: 1877 has more cash than its total debt.

Reducing Debt: 1877's debt to equity ratio has increased from 25% to 43.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1877 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1877 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 12.4% each year.


Discover healthy companies